Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19195678 | 0.88 | GRM2 (0.61) | GRM2KCNH2 | |
| SCHEMBL17485546 | 0.87 | GRM2 (0.61) | GRM2 | |
| SCHEMBL17478016 | 0.84 | GRM2 (0.71) | GRM2KCNH2 | |
| SCHEMBL17490644 | 0.84 | GRM2 (0.71) | GRM2KCNH2 | |
| SCHEMBL17490646 | 0.84 | GRM2 (0.50) | GRM2KCNH2 | |
| SCHEMBL17485489 | 0.81 | GRM2 (0.68) | GRM2 | |
| SCHEMBL17490642 | 0.81 | GRM2 (0.53) | GRM2KCNH2 | |
| SCHEMBL17490641 | 0.81 | GRM2 (0.53) | GRM2KCNH2 | |
| SCHEMBL22492787 | 0.80 | GRM2 (0.61) | GRM2 | |
| SCHEMBL17485488 | 0.80 | GRM2 (0.60) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177995-A1 | RADIOLABELLED mGluR2 PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-17 | — | — | US | disclosed |
| US-10967078-B2 | Radiolabelled mGluR2 PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-10005785-B2 | Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20170217971-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10967078-B2 | Radiolabelled mGluR2 PET ligands | GRM2, GRM3, GRM1 | GRM2 1/4885KCNH2 1222/4885 |
| US-20170217971-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | GRM2 1/4885KCNH2 1222/4885 |
| US-10005785-B2 | Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors | GRM2, GRM5, GRM1 | GRM2 1/4885KCNH2 939/4885 |
| US-20210177995-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | GRM2 1/4885KCNH2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.